IMPAACT Studies in Development

The study you are looking for is in protocol development.

As the study protocol reaches Version 1.0, a study page will be developed.

  Study Number
(DAIDS ID)
Study Title Status

IMPAACT 2019

(38504)

Phase I/II study of the pharmacokinetics, safety, and tolerability of dolutegravir/lamivudine/abacavir (Triumeq®) in HIV-1-infected children less than 12 years of age

In Development

IMPAACT 2020

(38505)

Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Children (SMaRT Kids): A Phase III Randomized Multi-center Trial

In Development

IMPAACT 2017

(30070)

Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents

In Development

IMPAACT 2016

(38506)

Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence in Adolescents Living with HIV in Low Resource Settings

In Development

IMPAACT 2003B

(12041)

(Phoenix) Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients

In Development


Return to the full list of studies

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.